 |
| 21-May-13 | Reiterated |
Barclays |
Equal Weight |
$18 → $20 |
|
| 13-May-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$19 → $23 |
|
| 12-Apr-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$18 → $19 |
|
| 11-Feb-13 | Reiterated |
UBS |
Buy |
$24 → $23 |
|
| 11-Feb-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$15 → $18 |
|
| 07-Nov-12 | Upgrade |
Cantor Fitzgerald |
Hold → Buy |
$14 → $15 |
|
| 06-Sep-12 | Reiterated |
Cantor Fitzgerald |
Hold |
$22 → $14 |
|
| 09-Aug-12 | Upgrade |
Needham |
Hold → Buy |
$20 |
|
| 01-May-12 | Reiterated |
Cantor Fitzgerald |
Buy |
$22 → $26 |
|
| 17-Apr-12 | Initiated |
Auriga |
Hold |
$16 |
|
| 09-Dec-11 | Initiated |
Barclays Capital |
Equal Weight |
$18 |
|
| 10-Nov-11 | Reiterated |
UBS |
Buy |
$28 → $24 |
|
| 16-Feb-11 | Reiterated |
RBC Capital Mkts |
Outperform |
$26 → $28 |
|
| 10-Sep-10 | Reiterated |
RBC Capital Mkts |
Outperform |
$32 → $24 |
|
| 23-Jul-10 | Initiated |
RBC Capital Mkts |
Outperform |
$30 |
|
| 17-May-10 | Upgrade |
Jefferies |
Hold → Buy |
$26.50 → $30 |
|
| 03-Feb-10 | Initiated |
Oppenheimer |
Outperform |
$33 |
|
| 02-Feb-10 | Upgrade |
Caris & Company |
Average → Buy |
$30 → $35 |
|
| 28-Jan-10 | Downgrade |
Jefferies & Co |
Buy → Hold |
$26.50 |
|
| 25-Jan-10 | Downgrade |
Caris & Company |
Buy → Average |
$30 |
|
|
|
| 18-Jun-13 04:18PM | Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition PR Newswire |
| 10:30AM | WARNER CHILCOTT PLC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online |
| 08:00AM | Announcement Under Irish Takeover Rules Revision to Relevant Securities in Issue GlobeNewswire |
| 17-Jun-13 06:58PM | Cramer Makes the Case for M&A at CNBC |
| 14-Jun-13 11:34AM | Warner Chilcott: Should You Buy Joel Greenblatt's Latest Pick? at Motley Fool |
| 13-Jun-13 02:01AM | WARNER CHILCOTT PLC Files SEC form 8-K, Other Events EDGAR Online |
| 10-Jun-13 02:59PM | Tax leverage helps make Irish pharma a popular target at Reuters |
| 10:50AM | Actavis Challenges Patents Zacks |
| 07-Jun-13 04:47AM | Warner Chilcott gets show of support optionMONSTER |
| 05-Jun-13 07:10PM | Endo Health to slash 15 pct jobs, looks to sell some assets at Reuters |
| 12:45PM | Sweden's Meda sale talks founder on valuation: source at Reuters |
| 31-May-13 10:14AM | Could Warner Chilcott Receive a Higher Bid? at Motley Fool |
| 09:58AM | Is Actavis a Buy at This Price? at Motley Fool |
| 30-May-13 05:10PM | Seeing Is Believing With This Blockbuster Eye Deal at Motley Fool |
| 28-May-13 05:01PM | Warner Chilcott PLC (WCRX): Today's Featured Health Care Laggard at TheStreet |
| 04:03PM | Valeant: High Leverage And Aggressive Synergy Estimates Make Me Skeptical at Seeking Alpha |
| 11:57AM | Cash Dividend On The Way From Warner Chilcott (WCRX) at Forbes |
| 08:19AM | What WSJ Canada Is Reading Tuesday at The Wall Street Journal |
| 27-May-13 10:49AM | Valeant to focus on integration in 2013 after Bausch & Lomb deal - CEO at Reuters |
| 09:41AM | Canada's Valeant buys Bausch & Lomb at CNNMoney.com |
| 24-May-13 06:59PM | [$$] Bausch & Lomb Nears $9 Billion Sale at The Wall Street Journal |
| 04:50PM | [$$] Bausch & Lomb Nears $9 Billion Sale at The Wall Street Journal |
| 02:09PM | Valeant Stock Spikes On Possible Bausch & Lomb Deal at Investor's Business Daily |
| 02:08PM | Acquisition-hungry Valeant sets its sights on Bausch & Lomb: report at MarketWatch |
| 01:50PM | Valeant near deal to acquire Bausch & Lomb: source at Reuters |
| 01:35PM | Valeant near deal to acquire Bausch & Lomb -source at Reuters |
| 12:29PM | [$$] Bausch Nears Deal to Sell Itself for $9 Billion at The Wall Street Journal |
| 11:55AM | Value Investor Joel Greenblatt's Magically Cheap Stock Picks at Seeking Alpha |
| 10:51AM | Actavis Buys Warner Chilcott, Upside Seems Limited at Seeking Alpha |
| 02:36AM | Actavis To Increase Operational Synergies By Acquiring Warner at Seeking Alpha |
| 22-May-13 03:24PM | Warner Chilcott Stock Falls On Unusually High Volume (WCRX) at TheStreet |
| 08:34AM | The Zacks Analyst Blog Highlights: Actavis, Warner Chilcott, Bill Barrett, Linn Energy and Forest Oil Zacks |
| 06:45AM | Kasowitz Benson, Eversheds, Latham: Business of Law at Bloomberg |
| 21-May-13 05:23PM | After the close: Merck's mysterious gain; Warner and Actavis stay up at MarketWatch +5.17% |
| 04:05PM | Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal at Bloomberg |
| 04:00PM | Actavis to Buy Warner Chilcott Zacks |
| 03:31PM | The Deal: Actavis Extends Gains Following Warner Deal at TheStreet |
| 02:43PM | 4 Merger and Acquisitions Stock Stories For a Tuesday Appraisal at Wall St. Cheat Sheet |
| 02:09PM | Warner Chilcott Reaches New 52-Week High (WCRX) at TheStreet |
| 02:00PM | A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap at Investopedia |
| 11:23AM | Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons at Fortune |
| 12:01AM | Kasowitz Benson, Eversheds, Latham, Davis:Business of Law at Bloomberg |
| 12:01AM | Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal at Bloomberg |
| 20-May-13 07:07PM | Final Trade: Your First Move for Tuesday, May 21 at CNBC |
| 06:36PM | Actavis buying Warner Chilcott in $8.5B deal AP |
| 06:33PM | Actavis buying Warner Chilcott in $8.5B deal AP |
| 06:32PM | Everyone Wins From This Acquisition at Motley Fool |
| 06:07PM | Actavis, Warner Chilcott Stocks Rise On Merger News at Investor's Business Daily |
| 05:58PM | [video] Fast Money Final Trade at CNBC |
| 05:24PM | Wall Street ends flat on correction worries Reuters |
| 04:34PM | [$$] Actavis Charts New Course With Warner Deal at The Wall Street Journal |
| 04:29PM | Stocks Slip on Concerns Markets Are Overpriced at TheStreet |
| 04:27PM | Stocks End Lower; Dow, S&P Briefly Hit New Highs at CNBC |
| 04:24PM | Stocks End Lower Amid Fed Taper Talk at CNBC |
| 04:22PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 04:17PM | Merger Monday on Wall Street at CNNMoney.com |
| 03:16PM | Despite Large Gains, This Stock Is Still a Buy at Motley Fool |
| 03:08PM | Merger Monday on Wall Street at CNNMoney.com |
| 02:56PM | Mondays Movers: Yahoo gains on bold Tumblr deal at MarketWatch |
| 02:41PM | Daily Wrap: May 20, 2013 at Forbes |
| 02:30PM | [$$] Actavis to Buy Warner Chilcott at The Wall Street Journal |
| 02:27PM | Ireland Welcomes Watson Pharmaceuticals, an American Success at TheStreet |
| 02:21PM | Wall Street hovers near record levels as investors hesitate to jump in Reuters |
| 02:21PM | Actavis to buy Warner Chilcott in $5 billion stock deal Reuters |
| 02:14PM | Stocks Dip Amid Fed Taper Talk; Energy Gains at CNBC |
| 02:12PM | The biggest merger you didn't hear about today at Fortune |
| 02:05PM | Warner Chilcott downgraded to Hold from Buy at Needham theflyonthewall.com |
| 01:53PM | Actavis Execs May Love NJ, But Ireland Has Lower Taxes at Forbes |
| 01:50PM | [$$] Actavis Prepares for Its Next Act at Barrons.com |
| 01:41PM | News Summary: Actavis plans Warner Chilcott deal AP |
| 01:34PM | Stocks Flat; Dow, S&P Briefly Hit Fresh Highs at CNBC |
| 01:32PM | Actavis buying Warner Chilcott in $8.5B deal AP |
| 01:06PM | On The Fly: Midday Wrap at theflyonthewall.com |
| 12:28PM | Yahoo! Pays Big Bucks For Tumblr and 2 Other Hot Stocks to Watch at Wall St. Cheat Sheet |
| 12:04PM | Merger Monday on Wall Street at CNNMoney.com |
| 11:57AM | [video] Dow Dull Except for Deal Stocks at TheStreet |
| 11:54AM | Stocks Gain, Led by Energy; Nasdaq Tops 3500 at CNBC |
| 11:36AM | Actavis to Acquire Warner Chilcott in $8.5 Billion Deal at Motley Fool |
| 11:18AM | Actavis, Warner Chilcott Stocks Rise On Merger News at Investor's Business Daily |
| 11:16AM | Stocks Reverse Early Losses; Nasdaq Tops 3500 at CNBC |
| 11:16AM | [$$] Actavis to Buy Warner Chilcott at The Wall Street Journal |
| 11:15AM | Stocks Edge Higher on Yahoo!, Actavis Deals at TheStreet |
| 11:08AM | Actavis buying Warner Chilcott in $8.5B deal AP |
| 11:06AM | Three Reasons Actavis Is Buying Warner Chilcott at Forbes |
| 11:01AM | Stocks Waver; Nasdaq Crosses Above 3500 at CNBC |
| 10:46AM | Actavis to buy Warner Chilcott in $5 billion stock deal Reuters |
| 10:46AM | Gains in Actavis-Warner Chilcott deal already baked into shares at MarketWatch |
| 10:43AM | Actavis price target rasied to $145 from $124 at BMO Capital theflyonthewall.com |
| 10:39AM | Warner Chilcott Rises On Unusually High Volume (WCRX) at TheStreet |
| 10:32AM | [video] Faber Report: Royalty Pharma to Raise Elan Bid at CNBC |
| 10:19AM | Stocks Edge Higher as Yahoo!, Actavis Strike Deals at TheStreet |
| 10:01AM | The Deal: Actavis Plays Hunter in $8.5 Billion Deal for Ireland's Warner Chilcott at TheStreet |
| 09:44AM | [video] Monday, May 20: Traders Watching Yahoo Carefully at MarketWatch |
| 09:32AM | Stocks Slip at Open as Fed Worries Weigh at CNBC |
| 09:26AM | On The Fly: Pre-market Movers at theflyonthewall.com |
| 09:17AM | Wall Street to dip after records, acquisitions eyed Reuters |
| 09:15AM | [video] Faber Report: Actavis to Buy Warner Chilcott at CNBC |
| 09:14AM | Actavis Uses Surging Stock To Snap Up Warner-Chilcott For $5B Plus Debt at Forbes |
| 09:13AM | Stock Futures Slip as Investors Seek Clarity from Fed at TheStreet |
| 09:13AM | Futures Slip as Investors Seek Fed Clarity at TheStreet |
|
|
| Warner Chilcott Public Limited Company, a specialty pharmaceutical company, engages in the development, manufacture, promotion, and franchise of branded pharmaceutical products focusing on the women's healthcare, gastroenterology, urology, and dermatology markets. Its principal products include ACTONEL for the prevention and treatment of postmenopausal osteoporosis; ATELVIA for the treatment of postmenopausal osteoporosis; LOESTRIN 24 FE and LO LOESTRIN FE, which are oral contraceptives for the prevention of pregnancy; ESTRACE cream, a vaginal cream for the treatment of vaginal and vulvar atrophy; ASACOL for the treatment of ulcerative colitis for orally administered 5-aminosalicylic acid products and maintenance of remission; ASACOL HD for the treatment of active ulcerative colitis; ENABLEX for the treatment of overactive bladder; and DORYX, a tetracycline-class oral antibiotic for the treatment of severe acne. The company markets its products and services through wholesale pharmaceutical distributors, and retail drug store chains. It has collaboration agreement with Sanofi-Aventis U.S. LLC to co-develop and market ACTONEL. The company has operations primarily in the United States, Puerto Rico, the United Kingdom, the Republic of Ireland, Australia, and Canada. Warner Chilcott Public Limited Company was founded in 1968 and is headquartered in Dublin, Ireland. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| van Zoonen Marinus Johannes | President, Europe/Int'l & Mkt. | Apr 01 | Sale | 13.41 | 703 | 9,428 | 144,838 | Apr 01 04:39 PM | | CONNAUGHTON JOHN | Director | Mar 04 | Sale | 13.47 | 10,590,608 | 142,655,490 | 0 | Mar 06 05:12 PM | | Ellman Herman | Senior V.P., Clinical Devel. | Mar 01 | Sale | 13.38 | 1,666 | 22,293 | 181,223 | Mar 04 04:04 PM | | Gilligan Claire A | Senior V.P., Quality | Feb 28 | Sale | 13.46 | 2,354 | 31,694 | 77,632 | Mar 01 04:13 PM | | Rodriguez Rama Francisco | Senior V.P., Tech. Operations | Feb 28 | Sale | 13.46 | 820 | 11,040 | 30,529 | Mar 01 04:13 PM | | Cross Leland H | Senior V.P., Tech. Operations | Feb 28 | Sale | 13.46 | 1,324 | 17,826 | 204,826 | Mar 01 04:12 PM | | Fenton Andrew | Senior V.P., CIO | Feb 28 | Sale | 13.46 | 1,390 | 18,715 | 108,310 | Mar 01 04:11 PM | | Halstead Michael | Senior V.P., Corp. Development | Feb 28 | Sale | 13.46 | 1,747 | 23,521 | 52,206 | Mar 01 04:10 PM | | Howard Alvin D | Sr. V.P., Regulatory Affairs | Feb 28 | Sale | 13.46 | 1,728 | 23,265 | 99,689 | Mar 01 04:10 PM | | Boissonneault Roger M | CEO & President | Feb 28 | Sale | 13.46 | 18,730 | 252,175 | 2,312,618 | Mar 01 04:07 PM | | Herendeen Paul | Exec. V.P. and CFO | Feb 28 | Sale | 13.46 | 4,674 | 62,929 | 132,620 | Mar 01 04:08 PM | | Fuhrmann Rochelle | Senior V.P., Finance | Feb 28 | Sale | 13.46 | 1,728 | 23,265 | 56,546 | Mar 01 04:09 PM | | van Zoonen Marinus Johannes | President, Europe/Int'l & Mkt. | Feb 28 | Sale | 13.46 | 15,869 | 213,655 | 145,541 | Mar 01 04:19 PM | | van Zoonen Marinus Johannes | President, Europe/Int'l & Mkt. | Feb 27 | Option Exercise | 0.00 | 31,737 | 0 | 161,410 | Mar 01 04:19 PM | | Gilligan Claire A | Senior V.P., Quality | Feb 19 | Sale | 14.53 | 1,045 | 15,181 | 79,986 | Feb 21 04:11 PM | | Fenton Andrew | Senior V.P., CIO | Feb 19 | Sale | 14.53 | 419 | 6,087 | 109,700 | Feb 21 04:12 PM | | Howard Alvin D | Sr. V.P., Regulatory Affairs | Feb 19 | Sale | 14.53 | 767 | 11,143 | 101,417 | Feb 21 04:09 PM | | Cross Leland H | Senior V.P., Tech. Operations | Feb 19 | Sale | 14.53 | 553 | 8,034 | 206,150 | Feb 21 04:10 PM | | Ellman Herman | Senior V.P., Clinical Devel. | Feb 19 | Sale | 14.53 | 691 | 10,039 | 182,889 | Feb 21 04:11 PM | | van Zoonen Marinus Johannes | President, Europe/Int'l & Mkt. | Feb 19 | Sale | 14.53 | 2,562 | 37,220 | 129,673 | Feb 21 04:07 PM | | Fuhrmann Rochelle | Senior V.P., Finance | Feb 19 | Sale | 14.53 | 767 | 11,143 | 58,274 | Feb 21 04:06 PM | | Halstead Michael | Senior V.P., Corp. Development | Feb 19 | Sale | 14.53 | 419 | 6,087 | 53,953 | Feb 21 04:05 PM | | Boissonneault Roger M | CEO & President | Feb 19 | Sale | 14.53 | 7,928 | 115,176 | 2,331,348 | Feb 21 04:03 PM | | Herendeen Paul | Exec. V.P. and CFO | Feb 19 | Sale | 14.53 | 1,969 | 28,605 | 137,294 | Feb 21 04:04 PM | | Fenton Andrew | Senior V.P., CIO | Feb 01 | Sale | 14.18 | 996 | 14,121 | 94,649 | Feb 04 04:12 PM | | Ellman Herman | Senior V.P., Clinical Devel. | Feb 01 | Sale | 14.18 | 1,010 | 14,320 | 168,110 | Feb 04 04:11 PM | | Cross Leland H | Senior V.P., Tech. Operations | Feb 01 | Sale | 14.18 | 808 | 11,456 | 191,233 | Feb 04 04:11 PM | | Howard Alvin D | Sr. V.P., Regulatory Affairs | Feb 01 | Sale | 14.18 | 1,010 | 14,320 | 86,714 | Feb 04 04:10 PM | | Halstead Michael | Senior V.P., Corp. Development | Feb 01 | Sale | 14.18 | 998 | 14,150 | 38,902 | Feb 04 04:10 PM | | Gilligan Claire A | Senior V.P., Quality | Feb 01 | Sale | 14.18 | 1,377 | 19,523 | 65,561 | Feb 04 04:09 PM | | Fuhrmann Rochelle | Senior V.P., Finance | Feb 01 | Sale | 14.18 | 998 | 14,150 | 43,571 | Feb 04 04:08 PM | | van Zoonen Marinus Johannes | President, Europe/Int'l & Mkt. | Feb 01 | Sale | 14.18 | 13,790 | 195,517 | 132,235 | Feb 04 04:07 PM | | Herendeen Paul | Exec. V.P. and CFO | Feb 01 | Sale | 14.18 | 2,840 | 40,266 | 101,543 | Feb 04 04:03 PM | | Boissonneault Roger M | CEO & President | Feb 01 | Sale | 14.18 | 9,125 | 129,376 | 2,222,156 | Feb 04 04:02 PM | | Gilligan Claire A | Senior V.P., Quality | Jan 30 | Sale | 13.38 | 489 | 6,545 | 66,938 | Jan 31 04:48 PM | | Cross Leland H | Senior V.P., Tech. Operations | Jan 30 | Sale | 13.38 | 465 | 6,224 | 192,041 | Jan 31 04:48 PM | | Ellman Herman | Senior V.P., Clinical Devel. | Jan 30 | Sale | 13.38 | 586 | 7,843 | 169,120 | Jan 31 04:47 PM | | Fenton Andrew | Senior V.P., CIO | Jan 30 | Sale | 13.38 | 351 | 4,698 | 95,645 | Jan 31 04:47 PM | | Fuhrmann Rochelle | Senior V.P., Finance | Jan 30 | Sale | 13.38 | 282 | 3,774 | 44,569 | Jan 31 04:45 PM | | Howard Alvin D | Sr. V.P., Regulatory Affairs | Jan 30 | Sale | 13.38 | 591 | 7,910 | 87,724 | Jan 31 04:46 PM | | Halstead Michael | Senior V.P., Corp. Development | Jan 30 | Sale | 13.38 | 320 | 4,283 | 39,900 | Jan 31 04:45 PM | | Herendeen Paul | Exec. V.P. and CFO | Jan 30 | Sale | 13.38 | 2,208 | 29,552 | 104,383 | Jan 31 04:43 PM | | van Zoonen Marinus Johannes | President, Europe/Int'l & Mkt. | Jan 30 | Sale | 14.28 | 2,215 | 31,621 | 146,025 | Jan 31 04:44 PM | | Boissonneault Roger M | CEO & President | Jan 30 | Sale | 13.38 | 8,470 | 113,363 | 2,231,281 | Jan 31 04:43 PM | | Fenton Andrew | Senior V.P., CIO | Jan 22 | Sale | 13.50 | 621 | 8,383 | 95,996 | Jan 23 04:13 PM | | Ellman Herman | Senior V.P., Clinical Devel. | Jan 22 | Sale | 13.50 | 1,166 | 15,741 | 169,706 | Jan 23 04:12 PM | | Howard Alvin D | Sr. V.P., Regulatory Affairs | Jan 22 | Sale | 13.50 | 1,222 | 16,497 | 88,315 | Jan 23 04:10 PM | | Gilligan Claire A | Senior V.P., Quality | Jan 22 | Sale | 13.50 | 949 | 12,811 | 67,427 | Jan 23 04:11 PM | | Cross Leland H | Senior V.P., Tech. Operations | Jan 22 | Sale | 13.50 | 839 | 11,326 | 192,506 | Jan 23 04:10 PM | | Fuhrmann Rochelle | Senior V.P., Finance | Jan 22 | Sale | 13.50 | 488 | 6,588 | 44,851 | Jan 23 04:09 PM | | Halstead Michael | Senior V.P., Corp. Development | Jan 22 | Sale | 13.50 | 488 | 6,588 | 40,220 | Jan 23 04:08 PM | | Boissonneault Roger M | CEO & President | Jan 22 | Sale | 13.50 | 13,924 | 187,973 | 2,239,751 | Jan 23 04:06 PM | | Herendeen Paul | Exec. V.P. and CFO | Jan 22 | Sale | 13.50 | 4,305 | 58,117 | 106,591 | Jan 23 04:07 PM | | Murray Stephen P | Director | Nov 28 | Sale | 11.41 | 6,491,618 | 74,069,361 | 0 | Nov 30 03:11 PM | | Murray Stephen P | Director | Nov 20 | Sale | 11.66 | 5,000,000 | 58,300,000 | 6,491,618 | Nov 20 10:47 AM | | Gilligan Claire A | Senior V.P., Quality | Oct 01 | Sale | 13.55 | 264 | 3,577 | 68,376 | Oct 01 04:41 PM | | Halstead Michael | Senior V.P., Corp. Development | Oct 01 | Sale | 13.55 | 77 | 1,043 | 40,708 | Oct 01 04:40 PM | | JPMP MASTER FUND MANAGER L P | 10% Owner | Sep 11 | Sale | 13.10 | 28,762,425 | 376,787,768 | 87,216 | Sep 11 03:45 PM | | JP MORGAN PARTNERS BHCA LP | 10% Owner | Sep 11 | Sale | 13.10 | 28,762,425 | 376,787,768 | 87,216 | Sep 11 03:03 PM | | Herendeen Paul | Exec. V.P. and CFO | Sep 11 | Sale | 13.10 | 309,240 | 4,051,044 | 110,896 | Sep 12 04:10 PM | | Hara Izumi | Senior V.P. | Sep 11 | Sale | 13.10 | 126,993 | 1,663,608 | 73,885 | Sep 12 04:11 PM | | Howard Alvin D | Sr. V.P., Regulatory Affairs | Sep 11 | Sale | 13.10 | 147,639 | 1,934,071 | 89,537 | Sep 12 04:08 PM | | Ellman Herman | Senior V.P., Clinical Devel. | Sep 11 | Sale | 13.10 | 23,500 | 307,850 | 170,872 | Sep 12 04:07 PM | | Murray Stephen P | Director | Sep 11 | Sale | 13.10 | 14,000,000 | 183,400,000 | 11,491,618 | Sep 12 10:26 AM | | CONNAUGHTON JOHN | Director | Sep 11 | Sale | 13.10 | 12,890,449 | 168,864,882 | 11,491,622 | Sep 13 05:29 PM | | BAIN CAPITAL INVESTORS LLC | 10% Owner | Sep 11 | Sale | 13.10 | 12,890,449 | 168,864,882 | 11,491,622 | Sep 13 05:29 PM | | THL WC (Dutch) B.V. | 10% Owner | Sep 11 | Sale | 13.10 | 14,000,000 | 183,400,000 | 11,491,622 | Sep 13 04:54 PM | | ABBRECHT TODD M | Director | Sep 11 | Sale | 13.10 | 14,000,000 | 183,400,000 | 11,491,622 | Sep 13 04:53 PM | | Halstead Michael | Senior V.P., Corp. Development | Jul 02 | Sale | 17.96 | 355 | 6,376 | 40,785 | Jul 02 04:30 PM |
|
|
|
|
|
|
